ATE129901T1 - Verfahren und verwendung für ortspezifische aktivierung von substanzen. - Google Patents

Verfahren und verwendung für ortspezifische aktivierung von substanzen.

Info

Publication number
ATE129901T1
ATE129901T1 AT86100130T AT86100130T ATE129901T1 AT E129901 T1 ATE129901 T1 AT E129901T1 AT 86100130 T AT86100130 T AT 86100130T AT 86100130 T AT86100130 T AT 86100130T AT E129901 T1 ATE129901 T1 AT E129901T1
Authority
AT
Austria
Prior art keywords
site
antibody
substances
specific activation
inactive substance
Prior art date
Application number
AT86100130T
Other languages
English (en)
Inventor
Edgar Haber
Gary R Matsueda
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/689,851 external-priority patent/US5116613A/en
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE129901T1 publication Critical patent/ATE129901T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT86100130T 1985-01-08 1986-01-07 Verfahren und verwendung für ortspezifische aktivierung von substanzen. ATE129901T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/689,851 US5116613A (en) 1985-01-08 1985-01-08 Antibody-thrombolytic agent product and method of use
US77446985A 1985-09-10 1985-09-10

Publications (1)

Publication Number Publication Date
ATE129901T1 true ATE129901T1 (de) 1995-11-15

Family

ID=27104496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86100130T ATE129901T1 (de) 1985-01-08 1986-01-07 Verfahren und verwendung für ortspezifische aktivierung von substanzen.

Country Status (6)

Country Link
EP (1) EP0187658B1 (de)
JP (1) JP2573927B2 (de)
AT (1) ATE129901T1 (de)
AU (1) AU595173B2 (de)
DE (1) DE3650432T2 (de)
IL (1) IL77533A (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5357042A (en) * 1984-04-23 1994-10-18 The General Hospital Corporation Synthetic peptides capable of eliciting fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity
EP0241907A3 (de) * 1986-04-14 1989-09-13 The General Hospital Corporation Heterobifunktionelle Antikörper und Verfahren zur Verwendung derselben
US5716990A (en) * 1987-03-09 1998-02-10 Cancer Research Campaign Technology Limited Drug delivery systems
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5453359A (en) * 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
US5120834A (en) * 1988-06-13 1992-06-09 American Biogenetic Sciences, Inc. Fibrin-specific monoclonal antibody
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5162218A (en) * 1988-11-18 1992-11-10 The Regents Of The University Of California Conjugated polypeptides and methods for their preparation
KR900701847A (ko) * 1988-11-18 1990-12-04 원본미기재 복합 폴리펩티드, 그들의 제조 방법 및 사용 방법
CA2051436A1 (en) * 1989-04-03 1990-10-04 Christoph Bode Platelet specific immunoconjugates
DK176290D0 (da) * 1990-07-24 1990-07-24 Novo Nordisk As Terapeutisk og diagnostisk praeparat
EP0673391A4 (de) * 1991-10-01 1995-11-22 Gen Hospital Corp Auf der oberfläche von aktivierten blutplättchen exprimiertes aktivierungsabhängiges protein und dagegen gerichtete antikörper.
US5961973A (en) 1992-03-06 1999-10-05 Crea; Roberto Pathogen-targeted biocatalysts
US5302707A (en) * 1992-03-26 1994-04-12 Affymax Technologies N.V. 5-fluorouridine nucleoside phosphate compounds
US5446132A (en) * 1992-10-01 1995-08-29 The General Hospital Corporation Thrombin-activated platelet protein-2 (TAPP-2)
US20030017147A1 (en) * 1996-09-20 2003-01-23 Guy L Reed Composition and method for enhancing fibrinolysis
GB0108332D0 (en) * 2001-04-03 2001-05-23 Univ Durham Lectin directed prodrug delivery system
CN100482546C (zh) 2002-06-20 2009-04-29 株式会社吉野工业所 袋状吹塑成型容器
US11220680B2 (en) * 2018-11-21 2022-01-11 Immunwork Inc. Polypeptide for treating pathological blood clots

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2523445A1 (fr) * 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
EP0142905A2 (de) * 1983-03-30 1985-05-29 Bio-Response Inc. Therapeutisches Mittel für die Behandlung von Krankheiten wie Krebs
EP0146050B1 (de) * 1983-12-16 1990-07-04 Denis M. Callewaert Stellenselektiver Plasminogenaktivator und Verfahren zu seiner Herstellung und Verwendung

Also Published As

Publication number Publication date
JP2573927B2 (ja) 1997-01-22
DE3650432T2 (de) 1996-04-18
EP0187658A3 (en) 1988-09-07
AU5162285A (en) 1986-07-17
EP0187658A2 (de) 1986-07-16
AU595173B2 (en) 1990-03-29
EP0187658B1 (de) 1995-11-08
DE3650432D1 (de) 1995-12-14
IL77533A (en) 1990-11-05
JPS61239889A (ja) 1986-10-25

Similar Documents

Publication Publication Date Title
ATE129901T1 (de) Verfahren und verwendung für ortspezifische aktivierung von substanzen.
DE68920176D1 (de) Festphasenanalytische Vorrichtung und Verfahren zum Gebrauch derselben.
EP0424634A3 (en) Method and apparatus for heterogeneous chemiluminescence assay
GR3007381T3 (de)
ATE67598T1 (de) Mit antigenen oder antikoerpern beschichteter traeger.
DE69624920D1 (de) Testreagentien und Testvorrichtungen
DE68901632D1 (de) Reaktionsgefaess zur durchfuehrung von aufeinanderfolgenden analytischen testen.
DE68911674D1 (de) Testverfahren und reagenzsatz dazu.
ES8801440A1 (es) Un metodo de ensayo mejorado para la determinacion de analitos bioligicos tales como haptenos, antigenos ,receptores , farmacos y similares.
DE69733488D1 (de) Verfahren zur besserung der wiederfindung troponin i und t
ES8802258A1 (es) Un metodo cromatografico de afinidad para la determinacion de antigenos en liquidos biologicos
EP0279097A3 (de) Teststreifen für Immunassay
DE3584796D1 (de) Verfahren und vorrichtung zur durchfuehrung analytischer bestimmungen.
ES8302313A1 (es) "metodo para ensayar reacciones antigeno-anticuerpo".
ATE86386T1 (de) Vorrichtung fuer bindungstest.
ATE62347T1 (de) Bestimmung von chlamydia trachomatis.
ATE48037T1 (de) Verfahren und reagenz zur verwendung zur bestimmung von pivka-ii.
NO874453D0 (no) Fremgangsmaate til bestemmelse av anti-hiv, middel dertil og dets anvendelse i fremgangsmaaten.
ATE153134T1 (de) Immunoassayverfahren unter anwendung photothermischer strahlablenkungsspektroskopie
DE3485265D1 (de) Verfahren zur bestimmung eines polyvalenten antigens und reagenz hierfuer.
DE58907087D1 (de) Verfahren zur Bestimmung von für ein Antigen klassenspezifischen Antikörpern und dazu geeignetes Reagenz.
ES2054686T3 (es) Equipo de inmunoensayo.
ATE67597T1 (de) Verfahren und materialien zur durchfuehrung von spezifischen bindungstests.
DE3686717D1 (de) Immuntestverfahren.
EP0184701A3 (en) A method for determining a ligand

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee